New drug combo shows promise for early anal cancer

NCT ID NCT06493019

Recruiting now Disease control Sponsor: Dustin Deming Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can improve outcomes for people with early-stage anal cancer. About 23 participants will receive the combination treatment, followed by maintenance therapy. The main goal is to see how many patients have no cancer remaining after treatment, while also monitoring side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anal carcinoma anal squamous cell carcinoma anus neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAL CANCER

Contacts and locations

Locations

Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08903, United States
University of Maryland
RECRUITING

Baltimore, Maryland, 21201, United States
University of Wisconsin
RECRUITING

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.